S U M M AR Y There were significantly more diffuse and focal electroencephalographic abnormalities in 127 mentally retarded epileptic patients treated with phenytoin than in 68 epileptics without phenytoin. Phenytoin intoxication made the difference still more pronounced. Monitoring drug levels and electroencephalograms appears to be the method of choice for ensuring safe and effective medication in intractable epilepsy.
Epilepsy is compatible with many types of electroencephalographic abnormalities. Abnormal electroencephalograms (EEGs) are also recorded in mental retardation, where they may reveal the location, type, and severity of the central affection (Gibbs and Gibbs, 1965; Iivanainen, 1974) . In neuropharmacology, the EEG remains the most sensitive and recordable index of brain function in intact man; changes in frequency, power, and amplitude of waking and sleeping EEGs are the principal indices studied (Fink, 1969) .
Electroencephalography has commonly been used in epilepsy to monitor the therapeutic response. In patients receiving phenytoin, the EEG is thought to be modified only when dosages of this drug approach the toxic range (Roseman, 1961) . Electroencephalographic alterations then vary from slowing in the alpha frequency range in mild cases to marked delta activity in severe ones.
Diffuse EEG abnormalities with 4 to 7 Hz slow activity but not lateralised were recorded in about half of a group of epileptic patients all of whom showed clinical signs of phenytoin intoxication after oral administration of the drug (Jensen and Grynderup, 1966) . Moreover, an increased frequency of epileptic seizures has been reported to correlate positively with increases in the serum phenytoin level of, on average, 12 ,ug/ml or more (Stensrud and Palmer, 1964) .
This study examines the relationship between EEG abnormalities and the serum concentration of phenytoin in a group of mentally retarded epileptics whom we have earlier examined exhaustively (Viukari, 1970; Iivanainen, 1974) . We reported on the pneumoencephalographic findings, especially those indicative of cerebellar atrophy, as well as on the serum concentrations of phenytoin in these same patients (livanainen et al., 1977) . The preliminary results of the present study have been reported previously (Iivanainen and Viukari, 1977 The oral dosage of phenytoin averaged 5.6-1=2.4 mg/kg body weight. The serum concentration of this drug was assayed with an ultraviolet absorption procedure (for details see Viukari, 1970) in 84 patients receiving long-term phenytoin therapy and in most cases suspected of having phenytoin intoxication. These assays showed their mean serum concentration to be 23.3+1=13.8 ,tg/ml.
Phenytoin intoxication was diagnosed in 70 (55%) of the 127 patients treated with this drug: (1) from the typical clinical signs of such toxicity, which remitted at least partly when the dosage of phenytoin was reduced, and (2) from a serum phenytoin level 25-30 ,tg/ml or higher.
Phenytoin was the only antiepileptic drug given to 21 patients. Other drugs were administered as follows: phenobarbitone to 53 (40%) patients, primidone to 27 (21%), carbamazepine to seven (5%), sulthiame to 7 (5%), other anticonvulsants to six (5%), phenothiazines to 24 (18%), lynoestrenol to 12 (9%), benzodiazepines to 10 (8%), isoniazid to eight (6%), methylphenidate to three (2%), tetracyclines to three (2%), and other drugs to 14 (11%).
Electroencephalographic changes were not used as a criterion of severity of epilepsy nor as an aid for monitoring anticonvulsant treatment. At that time we tried to substitute phenytoin for sedative anticonvulsant drugs because the latter were thought to cause impairment of psychomotor functions of the mentally retarded epileptics. Thus, the severity of epilepsy was not a crucial factor in the decision to treat with phenytoin or not, but it must have contributed to the therapeutic efforts (using combinations of drugs and pushing the dosage higher).
ELECTROENCEPHALOGRAPHIC RECORDINGS
Recordings of the EEG (waking and asleep) were taken from 127 of the epileptic patients treated with phenytoin. The other four patients in this group could not be studied because of restlessness and are omitted from the results. Anxious patients received chloral hydrate or pentobarbitone sodium before recording the EEG. All EEGs were registered with an eight-channel Kaiser electroencephalograph, and were interpreted according to conventional methods and classified by the system of Dumermuth (1965 
Discussion
Correlations between the severity of epilepsy, high serum levels of phenytoin, and EEG abnormalities are difficult to interpret properly. Phenytoin can induce seizures in man, and a high dose of this drug has caused irritability, ataxia, and convulsions in experimental animals (Levy and Fenichel, 1965) . In a patient whose epilepsy is drug resistant, a vicious circle can be set up by increasing the dosage of phenytoin, thereby raising the serum concentration to a possibly toxic level, which in turn increases seizures. In a recent study in which the dosage of phenytoin given to 20 chronic epileptics was raised until therapeutic serum concentrations greater than 40 ,tmol/l (10 ,g/ml) had been attained, the frequency of major seizures increased in three patients (15%) (Lambie et al., 1976) . Unfortunately, EEGs were not recorded in these patients. Roseman (1961) reported that among the last 1000 epileptics that he treated with phenytoin, toxic effects developed in over 45%. There is evidence, therefore, that phenytoin intoxication may be a not infrequent cause of seizures. Perucca (1976) has drawn attention to the less videly known clinical features of intoxication with antiepileptic drugs, such as psychiatric and behavioural problems, an increased incidence of seizures, and choreoathetoid movements. Of his patients, 80 to 83% showed the characteristic EEG pattern of such toxicity (slowing of the background rhythms and impaired reactivity to eye opening, which improved after drug withdrawal). Ahmad et al. (1975) have also attributed involuntary movements and EEG changes to phenytoin intoxication. The findings of these authors support the view of Logan and Freeman (1969) that drug toxicity seems to interact with underlying cerebral disease, an observation that agrees well with our experience (Viukari, 1970; Iivanainen et al., 1977) .
The German literature also contains several reports of phenytoin toxicity associated with EEG changes (Muller and Muller, 1972) , and one report on an infrequent activation of focal abnormalities by phenytoin (Bente, 1975) . Moreover, according to Morrell et al. (1959) , although phenytoin may bring about improvement in a previously diffuse abnormal EEG, a localised focus of seizure activity will remain. Buchthal et al. (1960) reported that, although the reduction in paroxysmal activity in the EEG with attainment of a phenytoin serum level of 10 jg/ml or more was the general trend, a transient increase in the incidence of paroxysms sometimes occurred. Similar phenomena were reflected in the present cases of phenytoin intoxication.
When mental retardation occurs in combination with epilepsy, the underlying brain lesion is usually more severe, and EEG abnormalities are more frequent and often also more severe than when epilepsy is absent (Gibbs and Gibbs, 1965; Iivanainen, 1974) . Compared with the mildly retarded, severely retarded people have a greater frequency of EEG abnormalities and hence also a higher intake of antiepileptic drugs.
Our results show that EEG recording is a valuable method for detecting intoxication in patients receiving antiepileptic drugs. In our experience, when an EEG pattern compatible with phenytoin toxicity prompted the withdrawal of most of such drug therapy, the patient's mental and physical condition sometimes improved dramatically. Remarkably, even seizure frequency was often reduced. As Roseman put it as early as 1961; "the minimal early slowing of the alpha activity seems to act as a titrating endpoint. Once this point is reached, not only has the therapeutic dose been exceeded but toxic symptoms and signs may be expected. Therefore, it is useless to push the dosage higher, particularly if control of seizures has not been effected". Because some patients are extremely susceptible to phenytoin toxicity, monitoring only serum concentrations of the drug is not enough. Severe signs of intoxication have been reported in patients whose serum phenytoin concentration was only S ,umol/l (1 ,ug/ ml) (Levy and Fenichel, 1965; Ahmad et al., 1975) . Furthermore, in toxic combinations of anticonvulsant drugs, even though the serum concentrations of the individual drugs may be within their therapeutic range, EEG examination may reveal encephalopathy. Dow (1971) has suggested that EEG examination may be of value in assessing the severity of anticonvulsant-induced toxic states with folate deficiency and in monitoring the efficacy of replacement therapy. He reports on a patient receiving primidone in whom the EEG had had generalised continuous theta activity at 4 to 5 Hz and runs of delta activity down to 1.5 Hz. Reduction in dosage of primidone and treatment with folic acid brought the EEG back to within "normal limits".
Phenytoin encephalopathy is a rare syndrome of diminishing intellectual capacity combined with an increased frequency of seizures, and some diffuse, cerebellar, and even focal neurological signs, which are induced by phenytoin and reversed at least partly when the drug is withdrawn. This syndrome seems to produce EEG abnormalities (McLellan and Swash, 1974) similar to those recorded in our patients. Interestingly, phenytoin also slows the conduction velocity of peripheral nerves (Le Quesne et al., 1976) .
That, in our patients, toxic serum levels of phenytoin correlated with many abnormalities in the EEG may be noteworthy. Also, selective morphological changes in the cerebellum have been attributed to the long-term administration of phenytoin-for example, Ghatak et al. (1976) . We must be careful in assigning a cause and effect relationship to phenytoin administration. However, the EEG abnormalities of our patients with phenytoin might in part be attributed to this treatment. Previous results in this same series of patients showed that the degree of cerebellar atrophy correlated better with serum phenytoin concentrations than with the severity of epilepsy (livanainen et al., 1977) .
In patients who had frequent seizures, it was not possible to say which seizures were caused by the disease and which, if any, were brought on by phenytoin. Before any interrelationships among EEG abnormalities, serum phenytoin levels, and the severity of epilepsy can be established with certainty, prospective studies are needed in which serum phenytoin concentrations are monitored, the severity of epilepsy is determined as precisely as possible, and EEG abnormalities are identified before the medication and continuously assessed thereafter.
Demonstration of the importance of this last factor was a clear result of the present studynamely, that the continuous EEG monitoring of the effects of antiepileptic drugs is not only a useful but an essential adjunct to the successful treatment of severe epilepsy (cf. Porter et al., 1977) . 
